Kopran is currently trading at Rs. 26.80, up by 1.40 points or 5.51 % from its previous closing of Rs. 25.40 on the BSE.
The scrip opened at Rs. 27.00 and has touched a high and low of Rs. 27.20 and Rs. 25.60 respectively. So far 114080 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.30 on 08-Jan-2014 and a 52 week low of Rs. 12.00 on 25-Jun-2013.
Last one week high and low of the scrip stood at Rs. 25.40 and Rs. 20.50 respectively. The current market cap of the company is Rs. 99.19 crore.
The promoters holding in the company stood at 39.17 % while Institutions and Non-Institutions held 2.67 % and 58.16 % respectively.
Kopran has received Certificate of Compliance with principles and guidelines of Good Manufacturing Practice from United Kingdom, Medicines and Healthcare products Regulatory Agency (UKMHRA) for the Finished Dosage Forms facility located at Savroli, Khalapur, Khopoli manufacturing general capsules arid tablets. The approval for this facility shall enable the Company to supply Finished Dosage Forms to the UK and the European market for which necessary marketing tie-ups are being entered into.
The facility also has approvals from Regulatory Authorities of several countries all over the world including the Medicines Control Council, South Africa (MCC) and the Therapeutic Goods Administration, Australia (TGA).
Kopran is the group company of Parijat Enterprises. Kopran is currently an integrated Pharmaceutical Company manufacturing a large range of products. It manufactures both Active Pharmaceutical Ingredients and Finished Dosage Forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: